Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Joerger M, Stathis A, Metaxas Y, Hess D, Mantiero M, Mark M, Volden M, Kaindl T, Engelhardt M, Larger P, Lane H, Hafner P, Levy N, Stuedeli S, Sessa C, von Moos R. Joerger M, et al. Among authors: kaindl t. Invest New Drugs. 2020 Aug;38(4):1067-1076. doi: 10.1007/s10637-019-00850-z. Epub 2019 Aug 30. Invest New Drugs. 2020. PMID: 31471863 Free PMC article. Clinical Trial.
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Kristeleit R, Evans J, Molife LR, Tunariu N, Shaw H, Slater S, Haris NRM, Brown NF, Forster MD, Diamantis N, Rulach R, Greystoke A, Asghar U, Rata M, Anderson S, Bachmann F, Hannah A, Kaindl T, Lane HA, Larger PJ, Schmitt-Hoffmann A, Engelhardt M, Tzankov A, Plummer R, Lopez J. Kristeleit R, et al. Among authors: kaindl t. Br J Cancer. 2020 Oct;123(9):1360-1369. doi: 10.1038/s41416-020-1010-8. Epub 2020 Aug 3. Br J Cancer. 2020. PMID: 32741975 Free PMC article. Clinical Trial.
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Joerger M, Hundsberger T, Haefliger S, von Moos R, Hottinger AF, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Joerger M, et al. Among authors: kaindl t. Invest New Drugs. 2023 Apr;41(2):267-275. doi: 10.1007/s10637-023-01336-9. Epub 2023 Feb 16. Invest New Drugs. 2023. PMID: 36792805 Free PMC article. Clinical Trial.
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Holdhoff M, Ye X, Strowd RE, Nabors B, Walbert T, Lieberman FS, Bagley SJ, Fiveash JB, Fisher JD, Desideri S, Surakus T, Engelhardt M, Kaindl T, Lane HA, Litherland K, Grossman SA, Kleinberg LR. Holdhoff M, et al. Among authors: kaindl t. Neurooncol Adv. 2024 Aug 28;6(1):vdae150. doi: 10.1093/noajnl/vdae150. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39371261 Free PMC article.
14 results